Inflammatory cytokines inhibition

"Inhibition of inflammatory cytokines" refers to therapeutic strategies aimed at blocking the activity of cytokines that promote inflammation, such as tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). This approach is not a molecular target itself, but rather encompasses monoclonal antibodies, receptor antagonists, small molecule inhibitors, or decoy receptors designed to neutralize cytokines or block their signaling. These strategies are widely used to treat diseases driven by chronic or excessive inflammation, including autoimmune, rheumatic, and some neurodegenerative diseases. While effective, such therapies are associated with significant risks, notably impaired host defense against infection and challenges in targeting inflammation precisely at disease sites, sparing systemic immune function.

Other names

Inhibition of inflammatory cytokinesAnti-cytokine therapyCytokine antagonism

Neutralization of cytokines (e.g., antibodies against TNF-α, IL-1, IL-6); Blockade of cytokine receptors; Inhibition of cytokine signaling pathways (e.g., JAK/STAT pathway inhibitors); Decoy receptors binding cytokines, rendering them inactive